Whalesbook
1. THE SEAMLESS LINK
Motilal Oswal's latest research initiates coverage on Piramal Pharma with a 'Buy' recommendation and a price target of ₹190, signaling potential upside despite recent financial headwinds. This assessment comes on the heels of Piramal Pharma's third-quarter fiscal year 2026 performance, which fell short of revenue and EBITDA expectations. The company reported a net loss of ₹136 crore for the quarter, a notable shift from the ₹4 crore profit in the prior year, with revenue declining 3% year-on-year to ₹2,139.8 crore. The Contract Development and Manufacturing Organization (CDMO) segment, a key growth driver, saw revenue decrease by 9% year-on-year. Despite these challenges, management has reaffirmed its full-year FY26 guidance, suggesting an expectation of a stronger fourth quarter and underlying business improvement.
The Core Catalyst
Despite a challenging Q3FY26 where Piramal Pharma posted a net loss and missed revenue expectations, Motilal Oswal's 'Buy' rating and ₹190 target price indicate a contrarian view. The firm values Piramal on a Sum-of-the-Parts (SoTP) basis, applying multiples of 18x EV/EBITDA to the CDMO business, 11x to Complex Hospital Generics (CHG), and 13x to consumer health (ICH). This valuation approach underpins the target price, suggesting that the market may be overlooking short-term execution issues in favor of medium-term recovery prospects. On February 2, 2026, Piramal Pharma's stock traded around ₹151.89 to ₹155.2, with moderate trading volumes, indicating investor caution ahead of further clarity on the anticipated Q4 rebound. The stock's year-to-date performance has been weak, with a decline of approximately 34% over the past year, trading within its 52-week range of ₹148.31 to ₹240.95. This suggests significant room for appreciation if the company meets its projected turnaround.
The Analytical Deep Dive
Motilal Oswal's optimistic outlook is anchored by several factors, including early signs of recovery in the CDMO sector. Piramal Pharma has noted a significant increase in Request for Proposals (RFPs) and order inflows since October 2025, attributed to a gradual recovery in US bio-pharma funding. This trend is crucial for the CDMO segment, which has been impacted by inventory destocking and slower early-stage order inflows earlier in the fiscal year. The company's consumer health division, however, continues to show strength, with 20% year-on-year growth driven by its power brands. While regulatory delays have constrained growth in the Complex Hospital Generics (CHG) segment, the overall business strategy remains focused on integrated projects and expanding its capabilities. Furthermore, the Indian government's 'Biopharma Shakti' program, announced in the Union Budget 2026 with a ₹10,000 crore allocation, aims to bolster India's position as a biopharmaceutical manufacturing hub, potentially creating a more favorable operating environment for domestic players like Piramal Pharma. The CDMO market in India is projected to double in the next five years, shifting focus from cost to quality, regulatory readiness, and scalability, positioning well-capitalized players for growth.
Competitively, Piramal Pharma, with a market capitalization of approximately ₹20,629 crore, is a significant player in the Indian CDMO space, ranked among the top three domestically and among the top global contenders. However, it operates in a segment alongside larger pharmaceutical giants like Sun Pharma and Dr. Reddy's Laboratories, which command substantially higher market capitalizations. The company's negative P/E ratio of around -796.89 (TTM as of Jan 2026) reflects its recent profitability challenges, a stark contrast to many peers with positive P/E multiples. Despite a low Return on Equity (ROE) of 1.11% and a modest Return on Capital Employed (ROCE) of 6.45%, the brokerage's SoTP valuation suggests embedded value within its distinct business segments.
The Future Outlook
Piramal Pharma's management has maintained its guidance for FY26, expecting mid-single-digit revenue growth and EBITDA margins in the high-teens. This suggests confidence in a sequential improvement in performance, particularly in the fourth quarter, which is historically the strongest. The strategic acquisition of Kenalog for $35 million from Bristol Myers Squibb further signals a focus on inorganic growth and portfolio enhancement. The company's ongoing efforts towards cost optimization and operational excellence are expected to support profitability. Sustained recovery in biopharma funding and faster customer decision-making are identified as key drivers for healthy growth into FY27, with investments in expanding its Lexington and Riverview facilities on track. The brokerage's target price of ₹190 implies a substantial potential upside from current trading levels, contingent on the successful execution of its recovery strategy and favorable sector dynamics.